Analyzing Analyst Recommendations: Arbutus Biopharma Corporation (ABUS), Profire Energy, Inc. (PFIE)

Arbutus Biopharma Corporation (NASDAQ:ABUS) tinted loss of 0% (0 points) to US$3.89. The volume of 0.08 Million shares climbed down over an trading activity of 200.65 Million shares. EPS ratio determined by looking at last 12 month figures is -1.81. Over the same time span, the stock marked US$12.6 as its best level and the lowest price reached was US$3.2. The corporation has a market cap of US$207.49 Million.

Arbutus Biopharma Corporation (NASDAQ:ABUS)’s earnings per share has been growing at a -23.8 percent rate over the past 5 year when average revenue increase was noted as -5.4 percent. The return on equity ratio or ROE stands at -72.9 percent while most common profitability ratio return on investment (ROI) was -72.5 percent. The company’s institutional ownership is monitored at 43.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Profire Energy, Inc. (NASDAQ:PFIE) is worth US$80.74 Million and has recently fallen -1.18% to US$1.67. The latest exchange of 0.16 Million shares is below its average trading activity of 227.84 Million shares. The day began at US$1.69 but the price moved to US$1.69 at one point during the trading and finally capitulating to a session high of US$1.69. The stock tapped a 52-week high of US$5.3 while the mean 12-month price target for the shares is US$4.71.

Currently, the stock carries a price to earnings ratio of 12.37, a price to book ratio of 1.78, and a price to sales ratio of 1.76. For the past 5 years, the company’s revenue has grown 17.8%, while the company’s earnings per share has grown 23.3%. With an institutional ownership near 44.1%, it carries an earnings per share ratio of 0.14.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.